The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Abstract
Background Persistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of recurrent acute pancreatitis. Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides. Methods In a phase 3 trial, we randomly assigned 75 patients with persistent chylomicronemia (with or without a genetic diagnosis) to receive subcutaneous plozasiran (25 mg or 50 mg) or placebo every 3 months for 12 months. The primary end point was the median percent change from baseline in the fasting triglyceride level at 10 months. Key secondary end points were the percent change in the fasting triglyceride level from baseline to the mean of values at 10 months and 12 months, changes in the fasting apolipoprotein C-III level from baseline to 10 months and 12 months, and the incidence of acute pancreatitis. Results At baseline, the median triglyceride level was 2044 mg per deciliter. At 10 months, the median change from baseline in the fasting triglyceride level (the primary end point) was -80% in the 25-mg plozasiran group, -78% in the 50-mg plozasiran group, and -17% in the placebo group (P Conclusions Patients with persistent chylomicronemia who received plozasiran had significantly lower triglyceride levels and a lower incidence of pancreatitis than those who received placebo. (Funded by Arrowhead…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the phase 3 PALISADE trial [118], plozasiran reduced apoC-III by ~ 90% and TG by 78–80% at 10 months, achieving TG levels < 500 mg/dL in about half of patients and < 150 mg/dL in over 90% of those with partial LPL activity.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [118]
In the citing paper
“Ultimately, four RCTs met al.l eligibility criteria and were included in the final analysis [16, 17, 22, 23].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [17]
In the citing paper
“The meta-analysis included data from 4 clinical trials [16, 17, 22, 23], encompassing a total of 1,514 participants—534 assigned to various doses and treatment durations of plozasiran, and 980 receiving placebo.”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [17]
In the citing paper
“In contrast, recent trials by Watts et al. (2025) [17] and Gaudet et al. (2024) [23] demonstrated that plozasiran was able to achieve guideline-recommended triglyceride targets (< 500 mg/dL) and reduce the incidence of acute pancreatitis events [Watts 2025; Gaudet 2024].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [17]
In the citing paper
“Concerning safety findings for plozasiran, we observed slight increases in HbA1c, AST, and ALT levels, along with a higher incidence of headaches.”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [17]
In the citing paper
“Watts et al. (2025) focused on individuals with genetically confirmed familial chylomicronemia syndrome (FCS) or symptomatic persistent chylomicronemia, aiming to assess reductions in acute pancreatitis events [17].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [17]
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationJacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Self-citationClinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Self-citationBrunzell, J. D., Hazzard, W. R., Porte, D., & Bierman, E. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107334 · Cited by 484
Issues in Hypertriglyceridemic Pancreatitis
Scherer, J., Singh, V. P., Pitchumoni, C. S., & Yadav, D. K. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000436438.60145.5a · Cited by 482
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–180 of 180
Larouche, M., Ballantyne, C. M., Dufour, J., Brisson, D., Given, B. D., & Gaudet, D. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf146 · Cited by 1
“Considering that APOC3 inhibitors exhibit both LPL-dependent and LPL-independent mechanisms of action, most patients with severe HTG, including those with persistent chylomicronemia, are likely to respond [14].”
Self-citationCORE Principles in the Management of Severe Hypertriglyceridemia
Morris, P. B. (2026) · New England Journal of Medicine · doi:10.1056/nejme2517580 · Cited by 1
A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques
Fukase, T., & Dohi, T. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00104-x · Cited by 2
“In addition, it has recently reported that both olezarsen for patients with severe hypertriglyceridemia and plozasiran for patients with persis-tentchylomicronemiahaveasigni fi cantlygreaterreductionintheTGlevel and in the incidence of acute pancreatitis than placebo 122,123 .”
Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries
Haseef, M., Li, S. C. H., Gaitt, T., Chan, D. C., Pang, J., & Watts, G. F. (2026) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000955 · Cited by 1
Self-citationRNA interference for lipid disorders: is this the future?
Nassif, M., Fazoli, R. T., & Generoso, G. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001033 · Cited by 1
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome
Hang, S., & Hegele, R. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2646166 · Cited by 2
Self-citationFadah, K., Alomari, M., Elchouemi, M., & Lange, R. A. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02362-8 · Cited by 2
ApoC-III inhibition: from regulatory approval to equitable implementation
Gaudet, D., Larouche, M., & Stroes, E. S. G. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01281-z · Cited by 2
Self-citationRNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside
Ali, I., Qiu, J., Cheang, W. S., Wang, G., & Xu, S. (2026) · Research · doi:10.34133/research.1288 · Cited by 1
New drugs approved by the FDA in 2025: Synthesis and clinical applications
Liu, W., Li, X., Han, Y., Wu, L., Wang, M., Xuan, W., Xu, Z., Liu, W., Zhao, Q., & Hao, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118952 · Cited by 2
Remnant cholesterol — The transition from biomarker to risk factor
Rosenson, R. S., Velamuri, D. N., Muntner, P., & Goonewardena, S. N. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120755 · Cited by 3
Self-citationKirkpatrick, C. F., & Bittner, V. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.05.224 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 1
Self-citationHypertriglyceridaemia and its multifaceted mechanisms driving atherosclerotic cardiovascular disease
Li, X., Xu, L., Li, J., Luo, Y., Shen, H., & Zhang, D. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02983-6 · Cited by 2
“The incidence of pancreatitis was also significantly lower in the plo-zasiran group than in the placebo group (OR 0.17; 95% CI 0.03–0.94; P = 0.03) [91].”
InfluentialHegele, R. A. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001048 · Cited by 2
Self-citationUnmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk
Kypreos, K. E., Gafencu, A. V., Andreopoulou, O., Zvintzou, E., Marinos, K., Mparnia, V., Alemi, M., Daraban, B. S., Multescu, M. G., Ghinea, M., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19071071 · Cited by 2
Li, Y., Zhou, X., Wen, Y., Huang, Q., Yang, X., Mukherjee, R., Sutton, R., Liu, T., Cai, W., & Huang, W. (2026) · Biomedicines · doi:10.3390/biomedicines14071574 · Cited by 3
“Plozasiran, an APOC3-targeted small interfering RNA, also reduces TG levels in severe HTG and persistent chylomicronaemia, with emerging evidence of fewer pancreatitis events [148,149].”
SMASH: An initiative for equitable access to precision medicine for rare or severe lipid disorders
Larouche, M., Abifadel, M., Catapano, A. L., Cuchel, M., Santos, R. D., Raal, F. J., & Gaudet, D. (2024) · European Atherosclerosis Journal · doi:10.56095/eaj.v3i3.78 · Cited by 1
“Access might also be initially limited to patients presenting a genetic diagnosis of FCS, although some recent trials include patients presenting clinical features of FCS without carrying bi-allelic pathogenic variants [16].”
Self-citationDuell, P. B., & Maki, K. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.001 · Cited by 1
McCartney, F. (2025) · Therapeutic Delivery · doi:10.1080/20415990.2025.2469483 · Cited by 1
Plozasiran and Apolipoprotein C-III Inhibition
Schwartz, G. G., & Cobbaert, C. M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.519 · Cited by 1
PharmD, L. T., Trampoukis, C., & Polymenakos, K. (2025) · medRxiv · doi:10.1101/2025.07.16.25331632 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
“In the phase 3 PALISADE trial [118], plozasiran reduced apoC-III by ~ 90% and TG by 78–80% at 10 months, achieving TG levels 500 mg/dL in about half of patients and 150 mg/dL in over 90% of those with partial LPL activity.”
Quilomicronemia familiar: nuevas perspectivas
Echevarría, A. B., Corbo, M. J. A., Muñiz-Grijalvo, O., & Díaz-Díaz, J. L. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.10.006
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Tomlinson, B., & Chan, P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451752
“PALISADE (NCT05089084) was a phase 3 trial in 75 patients with persistent chylomicronemia who were randomized to receive subcutaneous plozasiran (25 mg or 50 mg) or placebo every 3 months for 12 months [62].”
Ramirez‐Cisneros, A., Stefanakis, K., & Mantzoros, C. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16194
“54,55 Results of the olezarsen and plozasiran studies are notably consistent; however, the plozasiran trial uniquely included patients without biallelic loss-of-function variants in APOC3, thus also addressing cases of multifactorial chylomicronaemia.”
Familial chylomicronemia: New perspectives
Echevarría, A. B., Corbo, M. J. A., Muñiz-Grijalvo, O., & Díaz-Díaz, J. L. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100747
The Importance of Hypertriglyceridemia: Risk of Atherosclerosis and Available Treatments
Hegele, R. A. (2025) · Canadian Cardiology Today · doi:10.58931/cct.2025.113
Self-citationDuell, P. B. (2025) · International Journal of Clinical and Translational Medicine · doi:10.53941/ijctm.2025.100008
“The incidence of acute pancreatitis was reduced 83% (odds ratio, 0.17; 95% CI, 0.03 to 0.94; p = 0.03) in the pooled plozasiran groups compared to placebo [17].”
InfluentialAlexander, V. J., Prohaska, T. A., Karwatowska‐Prokopczuk, E., Xia, S., & Tsimikas, S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.007
Evolving landscape for management of chylomicronemia
Maki, K. C., & Duell, P. B. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.012
Plozasiran senkt Triglyceride drastisch
Krome, S. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2539-6832
Thadchanamoorthy, V., Dayasiri, K. C., Yoganathan, H., Majitha, S. I., Hooper, A. J., & Burnett, J. R. (2025) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.70205
“Several new therapeutic agents are showing promise, including antisense oligonucleotides (ASO) e.g., olezarsen [13] and small interfering RNAs e.g., plozasiran [14].”
Teperikidis, E., Trampoukis, C., & Polymenakos, K. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001768 · Cited by 2
Olezarsen in moderate hypertriglyceridemia: The Essence-TIMI 73b trial
Gouni‐Berthold, I. (2025) · Med · doi:10.1016/j.medj.2025.100923
Familial chylomicronemia in children: clinical cases
Sadykova, D. I., Рашидовна, С. Д., Шакирова, А. Р., Sayfullina, R. M., Damotsev, I. V., Bulatova, А. K., Gagieva, Z. A., Хабибрахманова, З. Р., & Сластникова, Е. С. (2025) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2025-70-5-91-96
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Self-citationCardiovascular siRNA therapeutics: A global clinical trial landscape analysis
Yan, H., Zha, H., Chen, J., Wang, Z., & Pei, L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106596
Yao, L., Yang, X., Sutton, R., Xia, Q., & Huang, W. (2025) · MedComm · doi:10.1002/mco2.70554
Duell, P. B., & Maki, K. C. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.005
Genetic instruments and drug prediction: will APOC3 silencing reduce cardiovascular end points?
Hegele, R. A. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag018
Self-citationWie lässt sich das Pankreatitisrisiko senken?
Klose, G. (2026) · Gastro-News · doi:10.1007/s15036-025-3968-9
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 2
Self-citationLe syndrome d’hyperchylomicronémie familiale (SHF)
Langlois, C., & Charrière, S. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.01.003
The future of triglyceride-regulating therapies and registries
Watts, G. F., & Chan, D. C. (2026) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000951
Self-citationWulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
“…4 are other important regulators of the lipid metabolism as they also inhibit LPL. Conversely, therapeutic inhibition of apoCIII and ANGPTL3, -4, and -3/8 increases LPL activity, which is why these inhibitors are being tested as remnant cholesterol and triglyceride lowering drugs [9– 11,13–18,28].”
Horwacik, J., Maligłówka, M., Bułdak, Ł., & Okopień, B. (2026) · Livers · doi:10.3390/livers6020025
“Plozasiran was well tolerated, with a similar risk of adverse events across groups [124].”
Cardiovascular pharmacotherapy in 2025
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G., Drexel, H., Ferdinandy, P., Grove, E. L., Klingenberg, R., et al. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag016
Clinical identification of familial chylomicronemia syndrome and novel therapeutic options
Hang, S., & Hegele, R. A. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2661212
“At 10 months, median placebo-adjusted apo C-III reductions approached −90%, with TG reductions of −59% and −53% for the 25-mg and 50-mg doses, respectively ( p 0.001) [69].”
InfluentialSelf-citationEmara, A., Awashra, A., Aboeldahab, H. A., Gadelmawla, A. F., Abdul‐Hafez, H. A., Alharran, A. M., Alsubaiei, A. A., AlRumaihi, M. J., Albuhmaid, S. A., & Shubietah, A. R. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70220
Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention. Authors' Reply
Loomba, R. S., de‐Madaria, E., Afghani, E., Singh, V. K., & Leeper, N. J. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70692
“Genetic [7], mechanistic [6] and clinical data [8–11] collectively support APOC3 as a rational therapeutic target in conditions characterised by severe or refractory HTG.”
Self-citationЕпидемиология на фамилен хиломикронемичен синдром
Стефанов, Г., & Георгиева, М. (2026) · Редки болести и лекарства сираци · doi:10.36865/2026.v17i1.240
Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies
Chamerski, S., Wartecka-Zielińska, K., Pomorski, F., Karos, W., Marlęga-Linert, J., Marcinkowska, M., Stefańska, K., Grzybowska, M. E., Wydra, D. G., Gruchała, M., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1761761 · Cited by 2
“However, given that evidence is limited to a single case, no de fi nitive conclusions regarding maternal or fetal safety can be drawn (87, 88).”
Kessler, A. S., Serafini, P., Pushkarna, D., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.05.001
Sustained Approaches to Prevent Recurrence and Support Ongoing Diabetes Health
Ambawatiya, A., Goyal, K., Dahiya, R., Hyderi, Z., Singh, L. K., Srivastava, J., Kumar, N., & Abubakar, M. (2026) · Springer eBooks · doi:10.1007/978-981-95-8946-3_15
Masana, L., Ribalta, J., & Ibarretxe, D. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00102-6
Mourre, F., & Béliard, S. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.05.002
Clinical Pharmacology of Plozasiran
Huston, J., Orey, D., Corona, K., Ashchi, A., Ashchi, A., Deeb, E., Deeb, A., Rouhbakhsh, R., Berner, J., Sutton, D., et al. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00808-6
“The primary endpoint was median percent change from baseline in fasting triglyceride levels at 10 months, after receiving either plozasiran (25 mg or 50 mg) or placebo quarterly for 1 year [18].”
InfluentialKassem, B. A., Shaik, F. A., Sorour, O., Abdelhamid, A. H., Fazal, A., Dakroub, A. H., & Eid, A. H. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001846
Wang, L., He, M., Xie, H., Mao, W., Liu, Y., Ke, L., 邹鑫森, & Li, W. (2026) · European journal of medical research · doi:10.1186/s40001-026-04732-y
“Emerging triglyceride-lowering therapies targeting ApoC-III significantly reduce the occurrence of acute pancreatitis in patients with FCS [40–42].”
Ahn, C., Jeong, H., Yim, H. W., Kim, N. J., Han, S., & Oh, I. (2026) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2026.1855572
“…indications spanning both categories (Raal et al., 2023; Raal et al., 2020; Ray et al., 2017; Ray et al., 2020; Huo et al., 2024; Yamashita et al., 2024; Watts et al., 2025; Luo et al., 2023; Ballantyne et al., 2024; Gaudet et al., 2024; Wiegman et al., 2025; Koren et al., 2024; Taub et al., 2025).”
Gene Therapy for Lipid Management: Dawn of a New Era
Manoria, P. C. (2026) · Cureus · doi:10.7759/cureus.112496
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Self-citationHealthcare costs of recurrent acute pancreatitis hospitalizations
Desai, N. R., Kertesz, N. L., Kleinman, N. L., Watts, G. F., Rosenson, R. S., Kleinman, A., & Loomba, R. S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.031
Self-citationL’EMA approuve une molécule pour maladie rare : l’hypertriglycéridémie
Manus, J.-M. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76705-8
Paquette, M., Guay, S., & Baass, A. W. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.002
Self-citationKou, S., Qian, Y., Ding, X., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179244
Rodriguez-Montes, J., Hale, G. M., & Benny, T. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00638-6
“…main secondary endpoints included percent changes from baseline in ApoC-III at months 10 and 12, changes in non-high-density lipoprotein cholesterol (HDL-C), changes in low-density lipoprotein cholesterol (LDL-C), changes in apolipoprotein B, as well as the incidence of acute pancreatitis [13, 14].”
InfluentialForrest, A. S., Majety, P., Mayer, S., & Ganda, O. P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71180
Tsimikas, S., Morgan, E. S., Sharma, J., Lin, T., Mullick, A. E., Prakash, T. P., Swayze, E. E., & Prohaska, T. A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.012
Where we have come from and where we are going in lipid therapeutics
Goldberg, A. C., & Duell, P. B. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.001
To test or not to test: Indications and actionability in lipid genetics
Hegele, R. A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.023
Self-citationChooklin, S., & Chuklin, S. S. (2026) · Gastroenterology report · doi:10.1093/gastro/goag107
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Green, B., Leitersdorf, E., Shpitzen, S., Alyan, R., Schurr, D., Talmon, A., Tal, Y., Kaplan, M., Weiss, R., & Durst, R. Y. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101162 · Cited by 1
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
“The risk of HTG-associated acute pancreatitis (HTG-AP) increases in severe HTG and becomes particularly pronounced in extreme HTG, in which free fatty acid (FFA)-mediated lipo-toxicity and inflammatory pathways contribute to pancreatic injury [ 5, 6 ].”
Lee, C. H., Moon, H., Lee, K. H., Na, J. H., Choi, J. U., Choi, J. W., & Lee, S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115431
Tsimikas, S., Yang, X., Waldman, E., Lyu, F., Alexander, V. J., & Marcovina, S. M. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101164
siRNA therapeutics: from hepatic delivery to extrahepatic targeting
Wang, N., Meng, L., Shi, J.-X., & Bartneck, M. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2754564
Widjaja, J. S., Adji, A. S., Baraja, A., Dharmasaputra, A., Rosyadi, R. N., Komalasari, I., Mustofa, A., Multazam, C. E. C. Z., Alkaff, F. F., & Saputra, P. B. T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179420
Metadata
- Authors
- Watts, G. F., Rosenson, R. S., Hegele, R. A., Goldberg, I. J., Gallo, A., Mertens, A., Baass, A., Zhou, R., Muhsin, M., Hellawell, J., Leeper, N. J., & Gaudet, D.
- Affiliations
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-09
- Volume
- 392
- Issue
- 2
- Pages
- 127-137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402146754
- Semantic Scholar
- 7e77ad0e7b828bad027c2dd2d373cdb99622ce79
- Cited by
- 178
- References
- 42
- Citations by year
- 2026: 82 · 2025: 81
- FWCI
- 47.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Arrowhead Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- plozasiran, familial chylomicronemia syndrome, acute pancreatitis, apolipoprotein C-III, triglycerides, siRNA, hypertriglyceridemia, hyperglycemia, adverse events, prediabetes, diabetes mellitus, familial hypertriglyceridemia, familial combined hyperlipidemia
- MeSH terms
- Acute Disease, Adult, Aged, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Hyperlipoproteinemia Type I, Male, Middle Aged, Pancreatitis, Triglycerides, Incidence, RNA, Small Interfering, Apolipoprotein C-III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
